New test developed to simplify the diagnosis of allergies

EC5004 is a GLP-1 inhibitor, a class of drugs developed to treat obesity and T2D. Credit: Alexanderstock23 via www.shutterstock.com AstraZeneca has fortified its participation in

Presentation A 38-year-old woman visited her doctor for discoloration that had developed on her trunk 2 months prior. On examination, extensive hyperpigmented, reticulated patches were

In a phase II trial of moderate-to-severe major depressive disorder, 6 weeks of intensive treatment with psilocybin or escitalopram (Lexapro) plus psychological support were tied